Diphyllin

CAS No. 22055-22-7

Diphyllin ( —— )

Catalog No. M23994 CAS No. 22055-22-7

Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 302 In Stock
10MG 483 In Stock
25MG 708 In Stock
50MG 963 In Stock
100MG 1287 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Diphyllin
  • Note
    Research use only, not for human use.
  • Brief Description
    Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling.
  • Description
    Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling.
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV-1;Vesicular stomatitis virus (VSV);Vacuolar type H+-ATPase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    22055-22-7
  • Formula Weight
    380.4
  • Molecular Formula
    C21H16O7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    COC1=C(C=C2C(=C1)C(=C3C(=C2O)COC3=O)C4=CC5=C(C=C4)OCO5)OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Anti-inflammatory activities of constituents isolated from Phyllanthus polyphyllus.J Ethnopharmacol. 2006 Jan 16;103(2):181-6.
molnova catalog
related products
  • NBD-556

    A potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction.

  • HIV-1 Integrase Inhi...

    A novel compound that disrupts the HIV-1 integrase LEDGF interaction.

  • BNM-III-170

    BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.